三期临床使用干细胞移植在克罗恩病患者体中培育新的免疫系统

2018-08-09 MedSci MedSci原创

一项由伦敦玛丽女王大学领导,医学研究委员会(MRC)和国家健康研究所(NIHR)合作资助了200万英镑的III期临床试验,正在尝试使用患者自己的干细胞移植,为患有克罗恩病的人"生长"新的免疫系统。

一项由伦敦玛丽女王大学启动,医学研究委员会(MRC)和国家健康研究所(NIHR)合作资助了200万英镑的III期临床试验,正在尝试使用克罗恩病患者自己的干细胞移植,于体内培育新的免疫系统。这项名为ASTIClite的临床试验将从伦敦、利物浦、谢菲尔德、剑桥、爱丁堡、诺丁汉和牛津招募患者,并将通过谢菲尔德大学的临床试验部门进行协调。

克罗恩病是一种慢性,可导致患者衰弱和疼痛的肠道疾病,目前正影响着英国超过115000人。克罗恩病会引起消化系统内层炎症,导致腹泻、极度疲劳和腹痛等症状,这些都严重影响了患者的生活质量。目前的治疗手段都是旨在降低患者炎症,或者通过手术移除疾病区域。更极端的情况是将肠转移到胃中的小袋用于收集粪便。

近年来,干细胞已被成功应用于替代多发性硬化患者的免疫系统,这项三期临床试验将研究使用类似的治疗方法是否可以用于降低肠道炎症,为克罗恩病患者带来希望。

Barts Health NHS Trust的首席研究员兼顾问James Lindsay教授说:"尽管引入了新药,但仍有许多患者对所有的治疗方法没有反应或逐渐失去反应。手术可能是患者恢复正常日常活动的选择,但在一些患者中并不适用。我们希望通过干细胞移植完全重置患者的免疫系统,从根本上改变疾病的进程。虽然这可能不是治愈方法,但它可能会让一些患者对以前无效的药物做出反应。"

在试验期间,患者将接受激素治疗和化学疗法以动员他们的干细胞。从患者的血液中收获细胞,进一步的化疗用于清除免疫反应。然后将干细胞重新回输到体内,培育出新的免疫细胞,为患者提供有效的免疫系统。从理论上讲,新的免疫系统将不再引起患者自身的肠道炎症,并且可以让患者对药物产生应答。

NIHR评估、试验和研究计划负责人汤姆·沃利教授说:“干细胞疗法是具有巨大潜力的研究手段。早期的研究已经显示出干细胞在替换受损组织中的作用。在克罗恩病中,这种方法将为患者的长期健康带来真正的益处。”

原始出处:


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-09-20 西西er

    您好,作者,这篇文章有后续吗?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 西西er

    在中国招募吗?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Mar 12 05:24:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658877, encodeId=09e016588e767, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Tue Sep 18 14:24:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345894, encodeId=6bd4345894af, content=您好,作者,这篇文章有后续吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Thu Sep 20 22:28:26 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689928, encodeId=95821689928ab, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Sat Jun 08 11:24:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337714, encodeId=f36d33e714b7, content=在中国招募吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/08/10/b92c6fe1729451c8d4b3a5c04e1396c6.jpg, createdBy=dfe32402282, createdName=西西er, createdTime=Fri Aug 10 14:36:35 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337672, encodeId=63d733e672f9, content=了解下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 10 07:47:07 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 kafei

    了解下谢谢

    0

相关资讯

CLIN CANCER RES:伊匹单抗联合来那度胺治疗干细胞移植后淋巴系统恶性肿瘤

造血干细胞移植后阻止或治疗淋巴系统恶性肿瘤复发需要完整的策略。CLIN CANCER RES近期发表了一篇文章,研究来那度胺是否可以增强CTLA-4抑制剂伊匹单抗的抗肿瘤效果

JCO:血液系统恶性肿瘤干细胞移植后认知功能

清髓性异体干细胞移植(HCT)后认知功能损害已得到公认,但是低强度异体或自体HCT后对认知功能的影响尚不清楚。JCO近期发表了一篇文章研究这一问题。

干细胞移植会成为肥胖症的治疗良药吗?

贝鲁特阿拉伯大学(Beirut Arab University,BAU)健康科学学院的一组科研人员通过研究脂肪衍生MSCs(AD-MSCs)对肥胖和相关并发症的影响和建立可行性动物模型,以证明其对人类临床治疗的效果。

Dilanubicel获得FDA快速通道资格用于血液肿瘤患者

Nohla制药是一家为血液系统恶性肿瘤和其他重症疾病患者提供全面细胞疗法的生物公司,近日宣布美国食品和药物管理局(FDA)已授予dilanubicel(NLA101)快速通道资格,用于接受同种异体脐带血移植的高风险血液系统恶性肿瘤的治疗。

JCO:干细胞移植治疗轻链淀粉样变:早期死亡率降低

自体干细胞移植(ASCT)用来治疗免疫球蛋白轻链(AL)淀粉样变患者的时间已超过20年。但是早期的实践经验发现治疗早期死亡率较高。JCO近期发表了一篇文章,研究20年间自体干细胞移植治疗轻链淀粉样变早期死亡率的变化。

FDA警告:供体干细胞移植后长期使用Zithromax(阿奇霉素)会增加癌症复发风险

对于接受供体干细胞移植的血液或淋巴结癌症患者,不应长期给予抗生素Zithromax(阿奇霉素)以预防某种炎症性肺病。临床试验的结果发现,在这些长期使用Zithromax(阿奇霉素)患者中,血液和淋巴结(包括死亡)的癌症的复发率增加。FDA正在审核其他数据,并会在审核完成后传达结论和建议。